Priority Review Granted to PD-L1/4-1BB Bispecific Antibody Opamtistomig, Accelerating Commercialization and Addressing Unmet Need in EP-NEC
NANJING, China, July 10, 2026 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK) today announced that the biologics license application (BLA) for Opamtistomig (LBL-024, a PD-L1/4-1BB bispecific...
Gene Solutions' SPOT-MAS 10 Places Asia-Led Cancer Screening Innovation in the Global Spotlight
A blood-based cancer screening technology developed in Asia is gaining international attention after real-world data from more than 84,145 individuals were presented at ASCO Breakthrough 2026 and highlighted by the American Society of Clinical...
Cohesity Secures Earliest Invented Patent in the Industry for GenAI Retrieval-Augmented Generation (RAG) Platform Built on Secondary Data
Patent validates Cohesity's architectural lead in applying GenAI to secondary data to unlock AI without data movement SINGAPORE, June 3, 2026 /PRNewswire/ -- Cohesity, a leader in AI-powered data security, today announced that the U.S. Patent and...
FDA Breakthrough Device Designation Marks Major Milestone for Gene Solutions' SPOT-MAS 10 Multi-Cancer Screening Test
SINGAPORE, May 28, 2026 /PRNewswire/ -- Gene Solutions, a global biotechnology company advancing accessible genomic solutions for cancer detection and precision oncology, today announced that the U.S. Food and Drug Administration has granted...
Dizal's ZEGFROVY® (Sunvozertinib) New Drug Application Accepted and Granted Priority Review by China National Medical Products Administration for First-Line Treatment of EGFR Exon 20 Insertion-Mutated Non-Small Cell Lung Cancer
SHANGHAI, May 27, 2026 /PRNewswire/ -- Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of oncology and hematological diseases, announced that the Center for Drug Evaluation (CDE) of China's...
The sNDA for Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First‑Line Treatment for PD-L1-positive NSCLC Accepted for Review by NMPA
CHENGDU, China, May 8, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company") announced that the sNDA (the "Application") for the Company's TROP2 ADC sacituzumab tirumotecan (sac-TMT, also known as...
LGHL ANNOUNCES THAT ITS WHOLLY-OWNED SUBSIDIARY HAS BEEN GRANTED EXCLUSIVITY TO FURTHER NEGOTIATIONS AND THE ENTERING INTO OF A FORMAL AGREEMENT IN RESPECT OF THE PROPOSED RESTRUCTURING OF SKYFAME REALTY (HOLDINGS) LIMITED (IN LIQUIDATION)
SINGAPORE, April 14, 2026 /PRNewswire/ -- Lion Group Holding Ltd. (the "Company" or "LGHL") is pleased to announce that its wholly-owned subsidiary, Lion Wealth Management Limited ("Lion Wealth"), has entered into an exclusivity agreement dated...
Abbisko Therapeutics' FGFR4 Inhibitor Irpagratinib Granted Orphan Drug Designation by EMA for Hepatocellular Carcinoma
SHANGHAI, April 1, 2026 /PRNewswire/ -- 31 March 2026, Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter, HKEX code: 02256) announced that its independently developed, highly selective, oral small-molecule FGFR4 inhibitor irpagratinib...
MVC's ENVACGEN® is Granted First Enterovirus A71 Vaccine Marketing Authorization in Vietnam; Joins Forces with Substipharm Biologics to Expand Southeast Asian Market
TAIPEI and GENEVA, March 18, 2026 /PRNewswire/ -- Medigen Vaccine Biologics Corp. (MVC) and Substipharm Biologics announced on March 17 that ENVACGEN®, an Enterovirus 71 (EV-A71) vaccine, has received marketing authorization from the Drug...
Court Authorizes Notice of Proposed Class Action Settlement for Farmers, Landscapers and Others Exposed to Weed Killers
ST. LOUIS, March 9, 2026 /PRNewswire/ -- Seeger Weiss LLP, Motley Rice LLC, Waters Kraus Paul & Siegel, Williams Hart & Boundas LLP, The Holland Law Firm, and Ketchmark & McCreight P.C. announce that the Circuit Court of the City of St....